Home > Financial Ratios > CONCORD DRUGS

CONCORD DRUGS
Core EBITDA Growth

    Back to All Ratios
CONCORD DRUGS is part of below Screeners ↓
Best Quarterly Growth Small Cap Stocks
Best 1M Momentum Small Cap Stocks
COMMUNITY POLL
for CONCORD DRUGS
Please provide your vote to see the results

CONCORD DRUGS Last 5 Year Core EBITDA Growth History

[Consolidated]

Mar2025Mar2024Mar2023Mar2022
   Core EBITDA Growth(%) 2.39-11.54-19.54-

What is the latest Core EBITDA Growth ratio of CONCORD DRUGS ?

The latest Core EBITDA Growth ratio of CONCORD DRUGS is 2.39 based on Mar2025 Consolidated results.
Year Core EBITDA Growth
Mar20252.39
Mar2024-11.54
Mar2023-19.54
Mar2022-

How is Core EBITDA Growth of CONCORD DRUGS Trending?

Years Core EBITDA Growth % Change
Mar2025 2.39
Positive
Mar2024 -11.54
Negative
Mar2023 -19.54
0
Mar2022 0 -

Other Financial Ratios of CONCORD DRUGS


Compare Core EBITDA Growth ratio of peers of CONCORD DRUGS

Peers & Returns Market Capitalization 1 Week 1 Month 1 Year
CONCORD DRUGS ₹105.2 Cr 2% 12.9% 22.6% Stock Analytics
SUN PHARMACEUTICAL INDUSTRIES ₹441,958.0 Cr -3% -5.2% 17.9% Stock Analytics
DIVIS LABORATORIES ₹247,576.0 Cr 0.2% 9.7% 56.1% Stock Analytics
TORRENT PHARMACEUTICALS ₹189,233.0 Cr 1.3% 2% 36.5% Stock Analytics
CIPLA ₹110,273.0 Cr -2.2% -6.6% -10.5% Stock Analytics
DR REDDYS LABORATORIES ₹96,906.4 Cr 1.4% -3.7% -8.8% Stock Analytics


CONCORD DRUGS Share Price vs Sensex


Share Price Returns(%) 1 Week 1 Month 1 Year
CONCORD DRUGS

2%

12.9%

22.6%

SENSEX

-2.3%

-4.1%

-7.4%


You may also like the below Video Courses